[Federal Register Volume 75, Number 154 (Wednesday, August 11, 2010)]
[Notices]
[Pages 48691-48692]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-19861]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Single Source Cooperative Agreement Award for the World Health
Organization (WHO) To Continue Development of Sustainable Influenza
Vaccine Production
AGENCY: Department of Health and Human Services, Assistant Secretary
for Preparedness and Response, Biomedical Advanced Research Development
Authority
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notification of Single Source Cooperative Agreement Award for
the World Health Organization (WHO) To Continue Development of
Sustainable Influenza Vaccine Production Capacity in Under-Resourced
Nations CFDA: 93.360.
Statutory Authority: Section 319L of the Public Health Service
(PHS) Act, 42 U.S.C. 247d-7e as amended by Title IV of the Pandemic
and All-Hazards Preparedness Act (PAHPA), Pub. L. 109-417; and the
Consolidated Appropriations Act, 2010, Pub. L. 111-117.
Amount of Single Source Award: $6,400,000.
Project Period: September 30, 2010 through September 29, 2013.
In FY 2010, BARDA plans to provide a Single Source Continuation
Award to the World Health Organization to support the International
Vaccine Production Capacity-Building Program. BARDA currently funds the
development of vaccine manufacturing capacity in ten developing and
emerging-economy countries worldwide via a cooperative agreement with
the World Health Organization (WHO). The WHO has proven to be a key
partner and integral to the success of the program, which has been in
existence since 2006. Continuing the partnership with the WHO will
prove critical to the long-term viability of this program while
bolstering the influenza vaccine manufacturing capabilities of resource
poor nations and global pandemic preparedness overall.
Single Source Justification: The International Vaccine Capacity
Building Program, supported by the Department of Health and Human
Services, Assistant Secretary for Preparedness and Response, Biomedical
Advanced Research and Development Authority was developed and has been
operational since 2006. In light of the threat of an influenza pandemic
it was originally designed with the goals of bolstering both
international and domestic pandemic preparedness and response. The
fundamental approach in achieving these goals has been through the
development of the influenza vaccine production capabilities of under
resourced nations in the hopes that they will ultimately be able to
produce vaccines to protect the local, regional, and international
public health. The program is supported by a collaborative of U.S.
Government agencies, international organizations, foreign ministries
and/or other foreign institutions dedicated to achieving these goals.
The WHO is the only global organization with the experience and
scientific standing to accomplish the program goals. It is the
recognized world health authority within the United Nations system.
Similarly, the liaison and support functions that the WHO plays within
the international vaccine production capacity building program cannot
be duplicated or replicated. Through standing consultation and dialog
with its members states on all aspects of public health, WHO is the
only partner able to ensure synchronization of building of production
capacity in developing countries for influenza vaccine with other
pandemic preparedness activities and with increase of demand for
seasonal influenza immunization.
The WHO's strong collaborative relationships with foreign
governments, programmatic support, and familiarity with international
vaccine production institutions have been and will be critical to the
future viability of this program. Over the history of the International
Vaccine Production Capacity Building program, the WHO has provided
unique and invaluable support to the project. Similarly, the WHO has
also independently funded other nations/institutions working to
strengthen their influenza vaccine production capacity; also
demonstrating
[[Page 48692]]
their commitment to the success of this program. The WHO represents a
key stakeholder in the implementation of the program; providing unique
functions, technical and scientific expertise, and capabilities that no
other organization in the world has.
Additional Information: The agency program contact is Dr. Michael
Perdue, whom can be contacted at (202) 260-0966 or
[email protected].
Dated: August 3, 2010.
Nicole Lurie,
Assistant Secretary for Preparedness and Response, U.S. Department of
Health and Human Services.
[FR Doc. 2010-19861 Filed 8-10-10; 8:45 am]
BILLING CODE 4150-37-P